LURASIDONE

Lurasidone is an atypical antipsychotic blocking dopamine D2 and serotonin 5‑HT2A/5‑HT7 receptors, used for schizophrenia and bipolar depression. Side effects include akathisia, nausea, somnolence, weight gain, and metabolic changes.

Product Description


Mechanism of Action

LURASIDONE (ID 29858) displays a high‑dimensional biochemical interaction profile, integrating catalytic‑domain modulation, multi‑axis signalling interference, mitochondrial‑network recalibration, ion‑flux redistribution, membrane‑potential rebalancing, cytoskeletal remodelling, redox‑equilibrium restructuring and transcription‑factor pathway reprogramming. Its molecular topology supports interaction with catalytic residues, allosteric microdomains, transmembrane helices, nucleotide‑binding pockets, redox‑buffer centres and polymeric scaffolding complexes, enabling wide‑band influence across metabolic, genomic, structural and electrophysiological layers.

At the signalling level, LURASIDONE may reconfigure phosphorylation landscapes spanning ERK/MAPK/JNK/p38 and PI3K–AKT axes, modulate G‑protein coupling states, reorganise Ca²⁺ microdomain geometry, adjust IP₃/DAG cascade topology, and recalibrate cAMP–PKA amplitude distributions. Mitochondrial effects can include ETC‑complex rebalancing, ATP/ADP flux modulation, ROS‑threshold displacement, membrane‑potential polarity shifts and bidirectional stress‑signal integration between ER and mitochondrial compartments.

Advanced Research Applications

  • Kinome‑scale catalytic‑cascade interference mapping
  • High‑resolution docking & conformational‑transition simulations
  • UPR/ER‑stress, mitophagy & autophagic‑flux network analysis
  • Full multi‑omics integration (RNA‑seq, proteomics, phosphoproteomics, metabolomics)
  • Cytoskeletal mechanics & polymer‑turnover/force‑distribution modelling
  • Cell‑fate pathway simulations (apoptosis, necroptosis, ferroptosis, parthanatos)
  • AI‑driven SAR/QSAR pipelines for compound‑performance prediction

Toxicodynamics & Hazard Spectrum

  • Rapid ROS escalation & antioxidant‑buffer saturation
  • Mitochondrial fragmentation or ETC‑axis suppression
  • Severe Na⁺/K⁺/Ca²⁺ ionic‑flux destabilisation
  • Cytoskeletal depolymerisation & membrane‑integrity loss
  • Hyperactivation of NF‑κB, STAT & IRF inflammatory regulators
  • Induction of multi‑axis programmed‑cell‑death pathways
  • Epigenetic drift including methylation/acetylation imbalance

For expert laboratory research only — not intended for biological or therapeutic exposure.

Datasheet


Molecular Formula

C28H36N4O2S

Molecular Weight

492.7 g/mol

CAS Number

367514-87-2

Storage Condition

Conditions for safe storage, including any incompatibilities: Keep container tightly closed in a dry and well-ventilated place. Containers which are opened must be carefully resealed and kept upright to prevent leakage. Recommended storage temperature -20 °C

Solubility

Solubility depends on solvent and conditions (e.g., pH). Please contact us for solvent-specific guidance.

Purity

Purity information is available upon request (COA).

Synonym

Lurasidone; 367514-87-2; lurasidona; lurasidonum; SM-13496 FREE BASE

IUPAC/Chemical Name

(1R,2S,6R,7S)-4-[[(1R,2R)-2-[[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]methyl]cyclohexyl]methyl]-4-azatricyclo[5.2.1.02,6]decane-3,5-dione

InChl Key

PQXKDMSYBGKCJA-CVTJIBDQSA-N

InChl Code

InChI=1S/C28H36N4O2S/c33-27-24-18-9-10-19(15-18)25(24)28(34)32(27)17-21-6-2-1-5-20(21)16-30-11-13-31(14-12-30)26-22-7-3-4-8-23(22)35-29-26/h3-4,7-8,18-21,24-25H,1-2,5-6,9-17H2/t18-,19+,20-,21-,24+,25-/m0/s1

References

https://pubchem.ncbi.nlm.nih.gov/compound/213046;

3D Conformer.

(Click, turn or enlarge)

Download our GMP API Product List.

MedicaPharma is an EU-based supplier of GMP-certified APIs that serves leading healthcare institutions and research organizations.
Click here to download our full API product list.

Download